IMNEWRUN Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
38
- Latest Deal Type
-
Later Stage VC
- Investors
-
11
IMNEWRUN General Information
Description
Developer of precision-engineered antibody-based brain delivery therapeutics designed to address neurological disorders. The company's platform leverages structural biology, artificial intelligence, and cryo-electron microscopy to engineer antibodies capable of crossing the blood-brain barrier with high selectivity, integrating drug development capabilities within an enterprise-academia research infrastructure, enabling neuroscience researchers and healthcare stakeholders to advance treatment of complex brain diseases with greater precision and scientific rigor.
Contact Information
Website
www.imnewrun.comCorporate Office
- 5th Floor, North Center Building A
- 2066, Seobu-ro, Jangan-gu
- Suwon, Gyeonggi 16419
- South Korea
Corporate Office
- 5th Floor, North Center Building A
- 2066, Seobu-ro, Jangan-gu
- Suwon, Gyeonggi 16419
- South Korea
IMNEWRUN Timeline
IMNEWRUN Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 13-May-2026 | Completed | Pre-Clinical Trials | |||
| 7. Grant | 22-Aug-2024 | Completed | Pre-Clinical Trials | |||
| 6. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 5. Accelerator/Incubator | 31-May-2024 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 01-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 28-May-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 28-Sep-2020 | $8.53M | $17.1M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 03-Jul-2019 | $8.54M | $8.54M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
IMNEWRUN Patents
IMNEWRUN Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024091079-A1 | Blood-brain barrier permeable fusion protein and uses thereof | Inactive | 28-Oct-2022 | ||
| WO-2024080843-A1 | Blood-brain barrier permeable fusion protein and use thereof | Inactive | 14-Oct-2022 | ||
| AU-2022428997-A1 | Blood-brain barrier permeable fusion protein and uses thereof | Active | 31-Dec-2021 | ||
| AU-2022428997-B2 | Blood-brain barrier permeable fusion protein and uses thereof | Active | 31-Dec-2021 | ||
| EP-4458848-A1 | Blood-brain barrier permeable fusion protein and uses thereof | Pending | 31-Dec-2021 | C07K14/70582 |
IMNEWRUN Signals
IMNEWRUN Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hyosung Ventures | Corporate Venture Capital | Minority | ||
| Endless Frontier Labs | Accelerator/Incubator | |||
| Korea Dementia Research Center (KDRC) | Corporation | Minority | ||
| GTO Investment | Venture Capital | Minority | ||
| InterVest | Venture Capital | Minority |
IMNEWRUN FAQs
-
When was IMNEWRUN founded?
IMNEWRUN was founded in 2019.
-
Where is IMNEWRUN headquartered?
IMNEWRUN is headquartered in Suwon, South Korea.
-
What is the size of IMNEWRUN?
IMNEWRUN has 38 total employees.
-
What industry is IMNEWRUN in?
IMNEWRUN’s primary industry is Biotechnology.
-
Is IMNEWRUN a private or public company?
IMNEWRUN is a Private company.
-
What is IMNEWRUN’s current revenue?
The current revenue for IMNEWRUN is .
-
How much funding has IMNEWRUN raised over time?
IMNEWRUN has raised $43.8M.
-
Who are IMNEWRUN’s investors?
Hyosung Ventures, Endless Frontier Labs, Korea Dementia Research Center (KDRC), GTO Investment, and InterVest are 5 of 11 investors who have invested in IMNEWRUN.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process